Free Trial

Amylyx Pharmaceuticals (AMLX) Financials

Amylyx Pharmaceuticals logo
$4.88 +0.09 (+1.94%)
As of 11:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Amylyx Pharmaceuticals

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-302 49 -198
Consolidated Net Income / (Loss)
-302 49 -198
Net Income / (Loss) Continuing Operations
-302 49 -198
Total Pre-Tax Income
-302 54 -198
Total Operating Income
-315 39 -201
Total Gross Profit
81 355 19
Total Revenue
87 381 22
Operating Revenue
87 381 22
Total Cost of Revenue
5.95 25 2.99
Operating Cost of Revenue
5.95 25 2.99
Total Operating Expenses
396 317 221
Selling, General & Admin Expense
114 188 127
Research & Development Expense
140 128 93
Other Operating Expenses / (Income)
119 0.00 -
Restructuring Charge
23 0.00 -
Total Other Income / (Expense), net
13 15 3.74
Interest & Investment Income
14 16 4.29
Other Income / (Expense), net
-1.21 -0.66 -0.55
Income Tax Expense
-0.39 5.03 0.77
Basic Earnings per Share
($4.43) $0.73 ($3.39)
Weighted Average Basic Shares Outstanding
68.14M 67.23M 58.50M
Diluted Earnings per Share
($4.43) $0.70 ($3.39)
Weighted Average Diluted Shares Outstanding
68.14M 69.99M 58.50M
Weighted Average Basic & Diluted Shares Outstanding
88.60M 67.78M 66.72M

Quarterly Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-38 -73 -73 -119 4.73 21 22 1.57 -43 -54
Consolidated Net Income / (Loss)
-38 -73 -73 -119 4.73 21 22 1.57 -43 -54
Net Income / (Loss) Continuing Operations
-38 -73 -73 -119 4.73 21 22 1.57 -43 -54
Total Pre-Tax Income
-38 -73 -73 -119 6.48 22 24 1.40 -42 -54
Total Operating Income
-41 -76 -76 -122 1.93 19 20 -2.05 -45 -55
Total Gross Profit
-0.67 0.42 -1.03 83 99 97 93 66 19 0.17
Total Revenue
-0.67 0.42 -1.02 89 108 103 98 71 22 0.35
Operating Revenue
-0.67 0.42 -1.02 89 108 103 98 71 22 0.35
Total Operating Expenses
40 76 75 205 97 79 72 68 64 55
Selling, General & Admin Expense
17 18 22 58 52 49 43 44 41 30
Research & Development Expense
23 57 23 37 45 30 29 24 23 25
Total Other Income / (Expense), net
2.47 2.96 3.59 3.58 4.54 3.69 3.81 3.46 2.47 0.80
Interest & Investment Income
2.32 3.10 4.07 4.33 4.37 4.18 3.89 3.72 3.16 0.60
Other Income / (Expense), net
0.16 -0.14 -0.48 -0.75 0.17 -0.49 -0.08 -0.26 -0.69 0.20
Income Tax Expense
-0.64 0.00 0.00 0.24 1.75 1.52 1.93 -0.17 0.58 -0.13
Basic Earnings per Share
($0.54) ($1.07) ($1.07) ($1.75) $0.07 $0.31 $0.33 $0.02 ($0.61) ($0.92)
Weighted Average Basic Shares Outstanding
68.14M 68.09M 68.02M 67.85M 67.23M 67.41M 67.23M 66.72M 58.50M 58.53M
Diluted Earnings per Share
($0.54) ($1.07) ($1.07) ($1.75) $0.07 $0.30 $0.31 $0.02 ($0.61) ($0.92)
Weighted Average Diluted Shares Outstanding
68.14M 68.09M 68.02M 67.85M 69.99M 69.75M 70.13M 70.86M 58.50M 58.53M
Weighted Average Basic & Diluted Shares Outstanding
88.60M 68.55M 68.08M 68.01M 67.78M 67.52M 67.38M 67.18M 66.72M 66.26M

Annual Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-92 108 13
Net Cash From Operating Activities
-168 12 -180
Net Cash From Continuing Operating Activities
-168 12 -180
Net Income / (Loss) Continuing Operations
-302 49 -198
Consolidated Net Income / (Loss)
-302 49 -198
Depreciation Expense
0.90 1.09 0.49
Amortization Expense
-9.86 -9.94 -2.06
Non-Cash Adjustments To Reconcile Net Income
189 37 23
Changes in Operating Assets and Liabilities, net
-46 -66 -3.28
Net Cash From Investing Activities
76 92 -239
Net Cash From Continuing Investing Activities
76 92 -239
Purchase of Property, Plant & Equipment
-0.16 -1.24 -2.53
Acquisitions
-36 0.00 -
Purchase of Investments
-232 -301 -416
Sale and/or Maturity of Investments
344 394 179
Net Cash From Financing Activities
0.35 3.54 432
Net Cash From Continuing Financing Activities
0.35 3.54 432
Other Financing Activities, net
0.35 3.54 231
Effect of Exchange Rate Changes
-0.44 0.16 -0.07
Cash Income Taxes Paid
0.71 6.39 0.03

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
5.56 -2.44 -96 0.35 35 -113 133 52 -45 41
Net Cash From Operating Activities
-59 -42 -67 -0.49 14 -5.17 8.61 -5.07 -50 -43
Net Cash From Continuing Operating Activities
-59 -42 -67 -0.49 14 -5.17 8.61 -5.07 -50 -43
Net Income / (Loss) Continuing Operations
-38 -73 -73 -119 4.73 21 22 1.57 -43 -54
Consolidated Net Income / (Loss)
-38 -73 -73 -119 4.73 21 22 1.57 -43 -54
Depreciation Expense
0.16 0.22 0.21 0.32 0.30 0.30 0.28 0.20 0.18 0.17
Amortization Expense
-1.79 -2.31 -3.18 -2.58 -2.57 -2.48 -1.98 -2.90 -1.86 -0.09
Non-Cash Adjustments To Reconcile Net Income
5.42 44 18 121 8.20 11 10 7.94 6.54 6.14
Changes in Operating Assets and Liabilities, net
-25 -11 -9.18 -0.31 2.89 -35 -22 -12 -12 4.66
Net Cash From Investing Activities
65 39 -29 0.82 21 -108 123 56 -228 84
Net Cash From Continuing Investing Activities
65 39 -29 0.82 21 -108 123 56 -228 84
Purchase of Property, Plant & Equipment
-0.02 0.02 -0.09 -0.07 -0.36 -0.36 -0.28 -0.25 -0.62 -0.46
Sale and/or Maturity of Investments
65 75 130 74 148 57 124 66 34 85
Net Cash From Financing Activities
0.11 0.08 0.03 0.13 0.23 0.89 1.38 1.04 232 -
Net Cash From Continuing Financing Activities
0.11 0.08 0.03 0.13 0.23 0.89 1.38 1.04 232 -1.52
Other Financing Activities, net
0.11 0.08 0.03 0.13 0.23 0.89 1.38 1.04 232 -1.52
Effect of Exchange Rate Changes
-0.53 0.24 -0.04 -0.11 0.24 -0.13 -0.02 0.08 0.51 -0.37
Cash Income Taxes Paid
0.97 0.02 -0.01 -0.28 11 -2.42 -2.56 0.00 0.05 -0.03

Annual Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
194 517 391
Total Current Assets
189 465 382
Cash & Equivalents
77 170 63
Short-Term Investments
99 201 284
Accounts Receivable
0.45 40 15
Inventories, net
0.00 38 9.77
Prepaid Expenses
12 15 10
Plant, Property, & Equipment, net
0.96 2.69 2.61
Total Noncurrent Assets
3.24 50 6.71
Other Noncurrent Operating Assets
3.24 50 6.71
Total Liabilities & Shareholders' Equity
194 517 391
Total Liabilities
29 84 51
Total Current Liabilities
28 82 47
Accounts Payable
2.94 22 6.26
Accrued Expenses
24 58 38
Other Current Liabilities
1.52 2.26 2.04
Total Noncurrent Liabilities
0.46 1.98 4.24
Noncurrent Deferred Revenue
0.00 0.00 0.00
Other Noncurrent Operating Liabilities
0.46 1.98 4.24
Commitments & Contingencies
0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
165 433 341
Total Preferred & Common Equity
165 433 341
Preferred Stock
0.00 0.00 0.00
Total Common Equity
165 433 341
Common Stock
772 738 695
Retained Earnings
-607 -305 -354
Accumulated Other Comprehensive Income / (Loss)
-0.09 0.20 -0.09

Quarterly Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
251 332 417 467 454 408 181
Total Current Assets
245 327 411 434 427 389 172
Cash & Equivalents
72 75 171 135 248 115 108
Short-Term Investments
163 235 203 220 110 231 55
Accounts Receivable
1.73 4.09 20 29 33 18 0.14
Inventories, net
0.00 0.00 0.00 32 25 13 0.56
Prepaid Expenses
9.14 13 17 17 12 13 8.34
Plant, Property, & Equipment, net
1.25 1.47 2.46 2.76 2.64 2.56 2.12
Total Noncurrent Assets
4.20 3.97 4.46 30 24 16 7.13
Other Noncurrent Operating Assets
4.20 3.97 4.46 30 24 16 7.13
Total Liabilities & Shareholders' Equity
251 332 417 467 454 408 181
Total Liabilities
55 71 93 48 67 55 37
Total Current Liabilities
54 70 92 46 64 52 33
Accounts Payable
1.49 4.96 21 6.37 25 11 7.05
Accrued Expenses
50 63 68 37 37 39 24
Other Current Liabilities
1.97 2.37 2.31 2.20 2.15 2.09 1.99
Total Noncurrent Liabilities
0.60 0.77 1.38 2.57 3.14 3.69 4.77
Other Noncurrent Operating Liabilities
0.60 0.77 1.38 2.57 3.14 3.69 4.77
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
196 261 324 418 386 353 144
Total Preferred & Common Equity
196 261 324 418 386 353 144
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
196 261 324 418 386 353 144
Common Stock
765 758 748 728 717 705 456
Retained Earnings
-569 -496 -424 -310 -331 -353 -312
Accumulated Other Comprehensive Income / (Loss)
0.64 -0.10 -0.08 -0.15 -0.07 0.03 -0.73

Annual Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
-77.06% 1,612.94% 7,700.00%
EBITDA Growth
-1,209.24% 114.40% -131.75%
EBIT Growth
-928.34% 118.89% -129.51%
NOPAT Growth
-725.70% 124.98% -143.49%
Net Income Growth
-712.42% 124.84% -125.60%
EPS Growth
-732.86% 120.65% 74.61%
Operating Cash Flow Growth
-1,506.55% 106.63% -140.47%
Free Cash Flow Firm Growth
-341.31% 76.71% 0.00%
Invested Capital Growth
-118.91% 1,079.33% 20.13%
Revenue Q/Q Growth
-55.53% 29.42% 6,343.48%
EBITDA Q/Q Growth
-14.83% 267.33% -6.32%
EBIT Q/Q Growth
-15.59% 512.57% -5.37%
NOPAT Q/Q Growth
-15.65% 1,514.06% -8.80%
Net Income Q/Q Growth
-16.29% 2,583.61% -7.80%
EPS Q/Q Growth
-15.97% 3,400.00% 51.36%
Operating Cash Flow Q/Q Growth
-76.31% 123.22% -13.54%
Free Cash Flow Firm Q/Q Growth
-64.70% 60.67% 0.00%
Invested Capital Q/Q Growth
69.27% -2.03% 65.86%
Profitability Metrics
- - -
Gross Margin
93.19% 93.32% 86.54%
EBITDA Margin
-371.86% 7.69% -915.25%
Operating Margin
-360.22% 10.19% -905.72%
EBIT Margin
-361.61% 10.02% -908.20%
Profit (Net Income) Margin
-345.36% 12.94% -892.38%
Tax Burden Percent
99.87% 90.74% 100.39%
Interest Burden Percent
95.63% 142.35% 97.87%
Effective Tax Rate
0.00% 9.26% 0.00%
Return on Invested Capital (ROIC)
-875.40% 126.36% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-845.67% 122.44% 0.00%
Return on Net Nonoperating Assets (RNNOA)
774.52% -113.62% 0.00%
Return on Equity (ROE)
-100.88% 12.73% -92.53%
Cash Return on Invested Capital (CROIC)
0.00% -53.48% 0.00%
Operating Return on Assets (OROA)
-88.86% 8.39% -81.23%
Return on Assets (ROA)
-84.87% 10.84% -79.82%
Return on Common Equity (ROCE)
-100.88% 12.73% -40.88%
Return on Equity Simple (ROE_SIMPLE)
-183.14% 11.37% -58.24%
Net Operating Profit after Tax (NOPAT)
-220 35 -141
NOPAT Margin
-252.16% 9.25% -634.00%
Net Nonoperating Expense Percent (NNEP)
-29.73% 3.92% -25.93%
Return On Investment Capital (ROIC_SIMPLE)
-133.71% 8.12% -
Cost of Revenue to Revenue
6.81% 6.68% 13.46%
SG&A Expenses to Revenue
130.86% 49.47% 571.88%
R&D to Revenue
160.56% 33.66% 420.38%
Operating Expenses to Revenue
453.41% 83.13% 992.25%
Earnings before Interest and Taxes (EBIT)
-316 38 -202
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-325 29 -203
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.57 2.29 7.19
Price to Tangible Book Value (P/TBV)
1.57 2.29 7.19
Price to Revenue (P/Rev)
2.97 2.61 110.13
Price to Earnings (P/E)
0.00 20.17 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 4.96% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 10.03 0.00
Enterprise Value to Revenue (EV/Rev)
0.95 1.63 94.52
Enterprise Value to EBITDA (EV/EBITDA)
0.00 21.25 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 16.32 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 17.68 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 52.23 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.92 -0.93 -1.03
Leverage Ratio
1.19 1.17 1.16
Compound Leverage Factor
1.14 1.67 1.13
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
-2.94 8.14 27.01
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 55.82%
Liquidity Ratios
- - -
Current Ratio
6.67 5.66 8.20
Quick Ratio
6.23 5.01 7.77
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-147 -33 -143
Operating Cash Flow to CapEx
-106,781.53% 960.44% -7,120.78%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.25 0.84 0.09
Accounts Receivable Turnover
4.31 13.76 0.00
Inventory Turnover
0.00 1.06 0.00
Fixed Asset Turnover
47.91 143.77 14.41
Accounts Payable Turnover
0.48 1.80 0.56
Days Sales Outstanding (DSO)
84.59 26.53 0.00
Days Inventory Outstanding (DIO)
0.00 344.99 0.00
Days Payable Outstanding (DPO)
766.42 203.14 648.11
Cash Conversion Cycle (CCC)
-681.83 168.38 -648.11
Capital & Investment Metrics
- - -
Invested Capital
-12 62 -6.34
Invested Capital Turnover
3.47 13.66 -3.12
Increase / (Decrease) in Invested Capital
-74 68 1.60
Enterprise Value (EV)
83 622 2,101
Market Capitalization
259 994 2,448
Book Value per Share
$2.40 $6.42 $5.14
Tangible Book Value per Share
$2.40 $6.42 $5.14
Total Capital
165 433 341
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-177 -371 -347
Capital Expenditures (CapEx)
0.16 1.24 2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-15 11 -11
Debt-free Net Working Capital (DFNWC)
161 383 336
Net Working Capital (NWC)
161 383 336
Net Nonoperating Expense (NNE)
81 -14 57
Net Nonoperating Obligations (NNO)
-177 -371 -347
Total Depreciation and Amortization (D&A)
-8.95 -8.85 -1.57
Debt-free, Cash-free Net Working Capital to Revenue
-17.71% 2.96% -51.38%
Debt-free Net Working Capital to Revenue
184.30% 100.48% 1,509.33%
Net Working Capital to Revenue
184.30% 100.48% 1,509.33%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($4.43) $0.73 ($3.39)
Adjusted Weighted Average Basic Shares Outstanding
68.14M 67.23M 58.50M
Adjusted Diluted Earnings per Share
($4.43) $0.70 ($3.39)
Adjusted Weighted Average Diluted Shares Outstanding
68.14M 69.99M 58.50M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
88.60M 67.78M 66.72M
Normalized Net Operating Profit after Tax (NOPAT)
-204 35 -141
Normalized NOPAT Margin
-233.85% 9.25% -634.00%
Pre Tax Income Margin
-345.81% 14.26% -888.89%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
-100.61% -99.59% -101.04% 24.10% 395.54% 29,666.09% 0.00% 0.00% 0.00% 21.05%
EBITDA Growth
-25,278.31% -585.21% -532.94% -2,395.89% 99.65% 129.50% 133.92% 89.51% -34.66% -135.40%
EBIT Growth
-2,023.85% -515.76% -481.56% -5,207.86% 104.65% 133.46% 137.06% 95.16% -29.40% -135.39%
NOPAT Growth
-2,114.18% -403.48% -387.49% -3,614.16% 104.53% 145.59% 148.91% 93.12% -57.49% -138.59%
Net Income Growth
-893.62% -447.98% -429.35% -7,652.00% 111.08% 138.87% 140.83% 103.29% -50.66% -132.29%
EPS Growth
-871.43% -456.67% -445.16% -8,850.00% 111.48% 132.61% 133.33% 102.15% 85.44% 73.10%
Operating Cash Flow Growth
-535.45% -704.22% -873.38% 90.36% 127.27% 88.00% 118.53% 87.52% -75.96% -106.46%
Free Cash Flow Firm Growth
167.69% 175.36% 199.12% -26.03% -104.18% -227.05% -1.33% -22.51% 0.00% 0.00%
Invested Capital Growth
-118.91% -160.28% -266.74% -800.56% 1,079.33% 441.26% 309.39% 148.91% 20.13% 0.00%
Revenue Q/Q Growth
-259.86% 140.66% -101.15% -18.26% 5.61% 4.56% 37.50% 226.38% 6,243.48% 0.00%
EBITDA Q/Q Growth
45.91% 2.32% 36.28% -75,287.95% -101.03% -12.85% 467.33% 89.32% 13.69% -0.20%
EBIT Q/Q Growth
46.58% 1.26% 37.52% -5,937.39% -88.45% -9.38% 969.11% 94.89% 16.89% -0.34%
NOPAT Q/Q Growth
46.27% 0.82% 37.54% -6,150.87% -91.90% -6.04% 906.97% 92.63% 18.45% -0.79%
Net Income Q/Q Growth
48.36% -0.01% 38.80% -2,610.95% -77.36% -5.35% 1,303.31% 103.68% 20.56% 0.58%
EPS Q/Q Growth
49.53% 0.00% 38.86% -2,600.00% -76.67% -3.23% 1,450.00% 103.28% 33.70% 1.08%
Operating Cash Flow Q/Q Growth
-41.95% 37.56% -13,515.54% -103.61% 362.16% -160.04% 269.74% 89.79% -15.37% 7.28%
Free Cash Flow Firm Q/Q Growth
-6.66% 100.83% 181.56% 55.73% -3.92% -164.14% -3.70% 28.27% -66.46% 18.16%
Invested Capital Q/Q Growth
69.27% 21.26% 0.72% -178.71% -2.03% 117.80% 317.11% 210.03% 65.86% -33.64%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 100.00% 0.00% 93.29% 91.37% 94.92% 94.32% 92.60% 87.11% 50.14%
EBITDA Margin
0.00% -18,722.60% 0.00% -141.18% -0.15% 15.63% 18.75% -7.02% -214.58% -15,769.86%
Operating Margin
0.00% -18,187.74% 0.00% -137.78% 1.78% 18.23% 20.57% -2.87% -203.76% -15,849.57%
EBIT Margin
0.00% -18,221.63% 0.00% -138.62% 1.94% 17.75% 20.49% -3.24% -206.91% -15,791.88%
Profit (Net Income) Margin
0.00% -17,476.92% 0.00% -134.01% 4.36% 20.35% 22.48% 2.20% -195.13% -15,581.45%
Tax Burden Percent
98.34% 100.00% 100.00% 100.20% 73.05% 93.23% 91.95% 112.12% 101.37% 99.77%
Interest Burden Percent
94.28% 95.91% 94.70% 96.48% 307.65% 122.92% 119.32% -60.60% 93.03% 98.90%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 26.95% 6.77% 8.05% -12.12% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -198,826.27% 0.00% 0.00% 17.80% 223.27% 477.55% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -198,819.57% 0.00% 0.00% 16.88% 221.94% 476.31% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 190,679.53% 0.00% 0.00% -15.66% -204.27% -463.81% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -8,146.74% -51.22% -21.00% 2.14% 19.00% 13.74% -50.19% -92.53% -127.76%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -53.48% -133.23% -342.98% -1,866.06% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -9,982.69% 0.00% -133.68% 1.63% 16.12% 11.58% -0.89% -18.51% -30.03%
Return on Assets (ROA)
0.00% -9,574.70% 0.00% -129.24% 3.66% 18.47% 12.71% 0.60% -17.45% -29.63%
Return on Common Equity (ROCE)
0.00% -8,146.74% -51.22% -21.00% 2.14% 19.00% 13.74% -50.19% -40.88% -127.76%
Return on Equity Simple (ROE_SIMPLE)
0.00% -132.24% -63.48% -21.91% 0.00% 0.44% -18.85% -42.24% 0.00% -127.76%
Net Operating Profit after Tax (NOPAT)
-28 -53 -53 -85 1.41 17 19 -2.30 -31 -38
NOPAT Margin
0.00% -12,731.42% 0.00% -96.44% 1.30% 16.99% 18.91% -3.22% -142.63% -11,094.70%
Net Nonoperating Expense Percent (NNEP)
-3.32% -6.70% -5.79% -9.26% 0.92% 1.33% 1.24% 1.29% -5.19% -19.04%
Return On Investment Capital (ROIC_SIMPLE)
-17.27% - - - 0.33% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 6.71% 8.63% 5.08% 5.68% 7.40% 12.89% 49.86%
SG&A Expenses to Revenue
0.00% 4,285.58% 0.00% 65.16% 48.17% 47.44% 44.18% 61.61% 186.63% 8,678.26%
R&D to Revenue
0.00% 13,807.69% 0.00% 41.30% 41.41% 29.25% 29.57% 33.87% 104.24% 7,221.45%
Operating Expenses to Revenue
0.00% 18,287.74% 0.00% 231.07% 89.59% 76.69% 73.75% 95.48% 290.87% 15,899.71%
Earnings before Interest and Taxes (EBIT)
-40 -76 -77 -123 2.11 18 20 -2.32 -45 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-42 -78 -80 -125 -0.17 16 18 -5.01 -47 -54
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.57 1.12 0.49 0.59 2.29 2.95 3.75 5.55 7.19 11.44
Price to Tangible Book Value (P/TBV)
1.57 1.12 0.49 0.59 2.29 2.95 3.75 5.55 7.19 11.44
Price to Revenue (P/Rev)
2.97 1.12 0.43 0.48 2.61 4.19 7.55 20.90 110.13 4,775.97
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 20.17 671.94 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 4.96% 0.15% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 10.03 13.87 37.53 231.11 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.95 0.00 0.00 0.00 1.63 2.99 5.69 17.21 94.52 4,304.69
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 21.25 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 16.32 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 17.68 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 52.23 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.92 -0.96 -1.03 -1.06 -0.93 -0.92 -0.97 -1.01 -1.03 -1.13
Leverage Ratio
1.19 1.17 1.21 1.22 1.17 1.15 1.17 1.15 1.16 1.26
Compound Leverage Factor
1.12 1.12 1.15 1.18 3.61 1.42 1.40 -0.70 1.08 1.25
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1.76 -0.05 0.07 0.71 7.91 16.19 13.44 21.23 28.33 23.95
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 55.82% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.67 4.55 4.66 4.48 5.66 9.52 6.67 7.54 8.20 5.27
Quick Ratio
6.23 4.38 4.48 4.30 5.01 8.43 6.10 7.04 7.77 4.98
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
45 49 24 -30 -67 -64 -24 -24 -33 -20
Operating Cash Flow to CapEx
-295,040.00% 0.00% -74,808.99% -729.85% 3,806.46% -1,447.90% 3,096.76% -2,028.80% -8,015.65% -9,385.19%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.25 0.55 0.76 0.96 0.84 0.91 0.57 0.27 0.09 0.00
Accounts Receivable Turnover
4.31 12.64 15.91 21.00 13.76 19.95 0.00 0.00 0.00 2.52
Inventory Turnover
0.00 0.00 0.00 0.00 1.06 1.15 0.00 0.00 0.00 0.31
Fixed Asset Turnover
47.91 97.92 145.38 158.63 143.77 120.61 85.39 48.67 14.41 0.16
Accounts Payable Turnover
0.48 3.90 1.38 1.62 1.80 2.82 0.84 0.80 0.56 0.02
Days Sales Outstanding (DSO)
84.59 28.87 22.95 17.38 26.53 18.29 0.00 0.00 0.00 144.94
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 344.99 318.01 0.00 0.00 0.00 1,194.74
Days Payable Outstanding (DPO)
766.42 93.65 263.56 225.29 203.14 129.60 432.17 459.01 648.11 14,965.00
Cash Conversion Cycle (CCC)
-681.83 -64.78 -240.61 -207.91 168.38 206.70 -432.17 -459.01 -648.11 -13,625.32
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-12 -38 -49 -49 62 63 29 6.97 -6.34 -19
Invested Capital Turnover
3.47 15.62 -30.78 -19.01 13.66 13.14 25.25 -25.71 -3.12 -0.04
Increase / (Decrease) in Invested Capital
-74 -102 -78 -56 68 82 43 21 1.60 -19
Enterprise Value (EV)
83 -14 -181 -182 622 879 1,092 1,612 2,101 1,485
Market Capitalization
259 221 129 192 994 1,234 1,449 1,957 2,448 1,648
Book Value per Share
$2.40 $2.88 $3.84 $4.78 $6.42 $6.21 $5.75 $5.29 $5.14 $2.46
Tangible Book Value per Share
$2.40 $2.88 $3.84 $4.78 $6.42 $6.21 $5.75 $5.29 $5.14 $2.46
Total Capital
165 196 261 324 433 418 386 353 341 144
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-177 -234 -310 -373 -371 -355 -357 -346 -347 -163
Capital Expenditures (CapEx)
0.02 -0.02 0.09 0.07 0.36 0.36 0.28 0.25 0.62 0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-15 -43 -53 -54 11 33 6.04 -8.24 -11 -23
Debt-free Net Working Capital (DFNWC)
161 191 257 319 383 388 363 337 336 140
Net Working Capital (NWC)
161 191 257 319 383 388 363 337 336 140
Net Nonoperating Expense (NNE)
9.09 20 19 33 -3.32 -3.44 -3.50 -3.87 11 15
Net Nonoperating Obligations (NNO)
-177 -234 -310 -373 -371 -355 -357 -346 -347 -163
Total Depreciation and Amortization (D&A)
-1.63 -2.08 -2.97 -2.27 -2.27 -2.18 -1.70 -2.70 -1.68 0.08
Debt-free, Cash-free Net Working Capital to Revenue
-17.71% -21.91% -17.80% -13.67% 2.96% 11.37% 3.15% -8.79% -51.38% -6,678.55%
Debt-free Net Working Capital to Revenue
184.30% 97.39% 85.90% 80.12% 100.48% 132.04% 189.35% 360.29% 1,509.33% 40,449.86%
Net Working Capital to Revenue
184.30% 97.39% 85.90% 80.12% 100.48% 132.04% 189.35% 360.29% 1,509.33% 40,449.86%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.54) ($1.07) ($1.07) ($1.75) $0.07 $0.31 $0.33 $0.02 ($0.61) ($0.92)
Adjusted Weighted Average Basic Shares Outstanding
68.14M 68.09M 68.02M 67.85M 67.23M 67.41M 67.23M 66.72M 58.50M 58.53M
Adjusted Diluted Earnings per Share
($0.54) ($1.07) ($1.07) ($1.75) $0.07 $0.30 $0.31 $0.02 ($0.61) ($0.92)
Adjusted Weighted Average Diluted Shares Outstanding
68.14M 68.09M 68.02M 67.85M 69.99M 69.75M 70.13M 70.86M 58.50M 58.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
88.60M 68.55M 68.08M 68.01M 67.78M 67.52M 67.38M 67.18M 66.72M 66.26M
Normalized Net Operating Profit after Tax (NOPAT)
-28 -53 -37 -85 1.41 17 19 -1.44 -31 -38
Normalized NOPAT Margin
0.00% -12,731.42% 0.00% -96.44% 1.30% 16.99% 18.91% -2.01% -142.63% -11,094.70%
Pre Tax Income Margin
0.00% -17,476.92% 0.00% -133.74% 5.97% 21.82% 24.44% 1.96% -192.48% -15,617.68%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

When does Amylyx Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amylyx Pharmaceuticals' net income changed over the last 2 years?

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$301.74 million in 2024, rising from -$198.38 million in 2022. The previous period was $49.27 million in 2023. Find out what analysts predict for Amylyx Pharmaceuticals in the coming months.

What is Amylyx Pharmaceuticals's operating income?
Amylyx Pharmaceuticals's total operating income in 2024 was -$314.73 million, based on the following breakdown:
  • Total Gross Profit: $81.42 million
  • Total Operating Expenses: $396.15 million
How has Amylyx Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' total revenue changed from $22.23 million in 2022 to $87.37 million in 2024, a change of 293.0%.

How much debt does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals' total liabilities were at $28.87 million at the end of 2024, a 65.6% decrease from 2023, and a 43.2% decrease since 2022.

How much cash does Amylyx Pharmaceuticals have?

In the past 2 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $62.53 million in 2022 to $170.20 million in 2023, and is currently $77.39 million as of their latest financial filing in 2024.

How has Amylyx Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' book value per share changed from 5.14 in 2022 to 2.40 in 2024, a change of -53.2%.



This page (NASDAQ:AMLX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners